Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Human tumor antigens recognized by T lymphocytes.

Human tumor antigens recognized by T lymphocytes. From the Ludwig Institutefor CancerResearch,BrusselsBranch,B-1200 Brussels,Belgium;and Cellular Genetics Unit, Universit~Catholique de Louvain, B-1200 Brussels,Belgium e have come a long way since the identification of the first human tumor antigen recognized by autologous CTL. This report provides a brief appraisal of these antigens and their potential for cancer immunotherapy. Our comments will be restricted to nonviral antigens. The initial work carried out on mouse tumors revealed two possible mechanisms for generating new antigens that might be suflficiendy tumor-specific to be of relevance to immunotherapy. The first mechanism involved a point mutation, and the second involved the transcriptional activation o f a gene not expressed in normal tissues (1-3). Subsequent work on mouse tumors provided two interesting examples of tumor antigens resulting from point mutations (4, 5). Tumor-specific Shared Antigens. Three families of genes that appear to code for highly specific tumor antigens have been identified so far, namely, the MAGE, BAGE, and GAGE genes (6-9). These genes are frequently expressed in a wide range of tumor types such as melanoma, lung carcinoma, sarcoma, and bladder carcinoma, but very rarely in other tumor types such as brain tumors, renal carcinoma, and leukemia (7, 10-12). The only normal tissues where expression http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Journal of Experimental Medicine Rockefeller University Press

Human tumor antigens recognized by T lymphocytes.

T Boon; P van der Bruggen
The Journal of Experimental Medicine , Volume 183 (3): 725 – Mar 1, 1996
Download PDF
5 pages

Loading next page...
 
/lp/rockefeller-university-press/human-tumor-antigens-recognized-by-t-lymphocytes-QQKYz40C8j

References (56)

Publisher
Rockefeller University Press
Copyright
Copyright © 1996 by The Rockefeller University Press
ISSN
0022-1007
eISSN
1540-9538
DOI
10.1084/jem.183.3.725
Publisher site
See Article on Publisher Site

Abstract

From the Ludwig Institutefor CancerResearch,BrusselsBranch,B-1200 Brussels,Belgium;and Cellular Genetics Unit, Universit~Catholique de Louvain, B-1200 Brussels,Belgium e have come a long way since the identification of the first human tumor antigen recognized by autologous CTL. This report provides a brief appraisal of these antigens and their potential for cancer immunotherapy. Our comments will be restricted to nonviral antigens. The initial work carried out on mouse tumors revealed two possible mechanisms for generating new antigens that might be suflficiendy tumor-specific to be of relevance to immunotherapy. The first mechanism involved a point mutation, and the second involved the transcriptional activation o f a gene not expressed in normal tissues (1-3). Subsequent work on mouse tumors provided two interesting examples of tumor antigens resulting from point mutations (4, 5). Tumor-specific Shared Antigens. Three families of genes that appear to code for highly specific tumor antigens have been identified so far, namely, the MAGE, BAGE, and GAGE genes (6-9). These genes are frequently expressed in a wide range of tumor types such as melanoma, lung carcinoma, sarcoma, and bladder carcinoma, but very rarely in other tumor types such as brain tumors, renal carcinoma, and leukemia (7, 10-12). The only normal tissues where expression

Journal

The Journal of Experimental Medicine – Rockefeller University Press

Published: Mar 1, 1996

There are no references for this article.